7,855 press releases indexed under healthcare.
PALM BEACH GARDENS, Fla., September 15, 2026--Dane Street, a leading national provider of Independent Medical Exams (IMEs) and Peer Reviews to the Insurance and Healthcare markets, is pleased to announce the addition of Ted Smith to the Leadership team, as Executive Vice President of IME Sales.
Recognized among nation's Top 50 children's hospitals for 18th consecutive year, with eight specialty programs ranked among the nation's best including all four institutes MIAMI, Sept. 15, 2026 /PRNewswire/ -- Nicklaus Children's Hospital is the No. 1 pediatric hospital* in Florida in U.S....
(PR-inside.com) Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs TORONTO, ON / ACCESS Newswire / September 15, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to strengthen and expand the intellectual property and regulatory portfolio supporting bucillamine across medical countermeasures ("MCMs") and rare diseases. Revive's objective is to build bucillamine into a differentiated therapeutic franchise with multiple potential development and commercialization pathways. The strategy is centered
(PR-inside.com) SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") is scheduled to start next week at an Ebola Treatment Center in the Ituri province. "NV-387 being an oral drug with broad-spectrum antiviral properties, everyone is rooting for it and hoping that it is effective against Ebola in the this clinical trial," ..
NASHVILLE, Tenn., September 15, 2026--HealthStream, Inc. (Nasdaq: HSTM) (the "Company"), a leading healthcare technology platform company for clinical workforce solutions, today announced the completion of a private placement transaction through which WJRJJ Ventures, LLC ("WJRJJ") acquired a total of 1.5 million shares of the Company’s common stock. In this transaction, the Company issued 1,355,932 shares of common stock to WJRJJ for approximately $40 million in cash at a purchase price of $29.5
(PR-inside.com) SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals. Dr. Jeff Gudin provided background on the Ensysce novel program to provide safer opioids for severe pain as well as a substantial background on complex pain, specifically Complex Regional Pain Syndrome Type 1 (CRPS). Dr. Richard Langford also outlined the novel approach to ..
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol
Under the direction of founder and medical director Dr. Nicole Nadel, the Charleston-based medical spa has been recognized in two of the region's most widely voted annual honors, reinforcing the practice's reputation for medical aesthetics care across the Lowcountry and South Carolina...
(PR-inside.com) Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on September 17, 2026 SAN FRANCISCO, CA / ACCESS Newswire / September 15, 2026 / Jaguar Health, Inc. ( Nasdaq:JAGX ) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio of 1-for-15, on Thursday, September 17, 2026 (the "Effective Date") in order to support the Company's compliance with Nasdaq's listing standards. The Company's Common Stock will begin trading on a ..
Improving care access and affordability while reducing bad debt by 20% plus ATLANTA, Sept. 15, 2026 /PRNewswire-PRWeb/ -- Curae® has announced the market introduction of its new and most advanced Patient Financing solution. The best non-recourse revolving line of credit suite to help...